This cross-sectional study of data from the National Comprehensive Cancer Network assesses the association of prostate-specific membrane antigen positron emission tomography with tumor upstaging risk in patients with high-risk prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.